Exact Sciences (EXAS) Stock Rising on Illumina Takeover Speculation
NEW YORK (TheStreet) -- Shares of Exact Sciences (EXAS) - Get Report are up 6.19% to $13.38 today on reports that the company may be acquired by Illumina (ILMN), TheFlyreports.
The company only has one commercial offering, Cologuard. It is a DNA screening test for colorectal cancer.
Exact Sciences is currently collaborating with the Mayo Clinic on future DNA tests including lung, pancreatic and esophageal cancers.
Exact Sciences is a Madison, WI-based molecular diagnostics company, and Illumina is a San Diego-based company offering sequencing for genetic analysis.
Separately, TheStreet Ratings rated this stock as a "sell" with a ratings score of D.
The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself.
You can view the full analysis from the report here: EXAS
Recently, TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this articles's author.